I respectfully disagree because SVR calculated on an ITT basis subsumes the effect of discontinuation from side effects. I.e., a given treatment regimen cannot boost the ITT SVR rate appreciably unless it is tolerable enough for patients to take it for the full course of treatment. If a regimen is efficacious and is tolerable enough for patients to take it for a full course of treatment, it’s tolerable enough to be a good business proposition.
Market Data 
Markets 
AI
